The current standard drug therapy for PD is dopamimetic drugs, such as DA precursor levodopa (L-3,4-dihydroxyphenylalanine, L-DOPA), DA receptor agonists, and monoamine oxidase-B (MAO-B) inhibitors (Armstrong and Okun, 2020). Here, MAOB is linked to Parkinson disease.